logo
  

AZN : Phase III Trial Of Ultomiris Meets Main Goal In Neuromyelitis Optica Spectrum Disorder

AstraZeneca Plc (AZN,AZN.L) said phase III CHAMPION-NMOSD trial results showed that Ultomiris or ravulizumab-cwvz achieved a statistically significant and clinically meaningful reduction in the risk of relapse i n adults with anti-aquaporin-4 antibody-positive (Ab+) neuromyelitis optica spectrum disorder or NMOSD compared to the external placebo arm from the pivotal Soliris PREVENT clinical trial.

According to the company, Ultomiris, long-acting C5 complement inhibitor, met the primary endpoint of time to first on-trial relapse, as confirmed by an independent adjudication committee. Notably, no relapse was observed in 58 patients over a median treatment duration of 73 weeks.

NMOSD is a rare disease in which the immune system is inappropriately activated to target healthy tissues and cells in the CNS. Approximately three-quarters of people with NMOSD are anti-AQP4 Ab+, meaning they produce antibodies that bind to a specific protein, aquaporin-4 (AQP4).

The binding can inappropriately activate the complement system, which is part of the immune system and is essential to the body's defence against infection, to destroy cells in the optic nerve, spinal cord and brain.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The US Centers for Disease Control and Prevention or CDC has ended recommendations for social distancing and quarantine with a view to minimize covid-19's impact on persons, communities, and health care systems. The agency also ended recommendation for test-to-stay in schools, CNN noted. Healthcare major Johnson & Johnson, which is in the middle of a talcum powder fiasco, said it is discontinuing talc-based JOHNSON'S Baby Powder globally in 2023. The company plans to transition to an all cornstarch-based baby powder portfolio. According to the company, the commercial decision to use cornstarch in all its baby powder products was made after conducting an assessment of its portfolio Walt Disney's streaming service Disney+ is rolling out its much-anticipated new ad-supported subscription plan for Disney+ in the U.S. as part of its bid to stem the loss and make its streaming business profitable after the services posted a hefty operating loss of more than $1 billion in the third quarter. It is also raising pricing for its bundled subscription plans with Hulu, ESPN+ and live TV.
Follow RTT